A phase 1 trial of 8-chloro-adenosine in relapsed/refractory acute myeloid leukemia: An evaluation of safety and pharmacokinetics.
Vinod PullarkatLisa S ChenJoycelynne PalmerJianying ZhangTimothy W SynoldRalf BuettnerLe Xuan Truong NguyenGuido MarcucciNi-Chun TsaiYan WangJames O'HearnVarsha GandhiSteven T RosenPublished in: Cancer (2023)
Given the cardiac adverse events observed, patients require monitoring for arrhythmias and QT interval during infusion. Although peripheral blood cytoreduction was observed, responses were transient, suggesting combination strategies will be required.
Keyphrases
- acute myeloid leukemia
- peripheral blood
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- acute lymphoblastic leukemia
- low dose
- peritoneal dialysis
- diffuse large b cell lymphoma
- left ventricular
- allogeneic hematopoietic stem cell transplantation
- heart failure
- multiple myeloma
- congenital heart disease
- blood brain barrier
- cerebral ischemia
- atrial fibrillation